Yew Bio-Pharm Group, Inc. reported consolidated earnings results for fourth quarter and year ended December 31, 2017. For the quarter, the company’s total revenues were $5,494,935 against $12,000,504 a year ago. Net income was a loss of $7.8 million, or a loss of $0.14 per diluted share, compared with a loss of $1.4 million in the year-ago quarter, or a loss of $0.03 per diluted share. For the year, the company’s total revenues were $40,539,690 against $51,348,082 a year ago. Income from operations was $3,324,654 against $2,121,358 a year ago. Income before provision for income tax was $3,213,648 against $2,024,900 a year ago. Net income was $3,213,034 against $2,006,891 a year ago. Basic and diluted net income per common share was $0.06 against $0.04 a year ago. Net cash used in operating activities was $2,620,269 against net cash provided by operations of $643,031 a year ago.